The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction

1.

Tao Z, Shi A, Zhao J (2015) Epidemiological perspectives of diabetes. Cell Biochem Biophys 73(1):181–185. https://doi.org/10.1007/s12013-015-0598-4 CrossRefPubMed

2.

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103(2):137–149. https://doi.org/10.1016/j.diabres.2013.11.002 CrossRefPubMed

3.

Meng JM, Cao SY, Wei XL, Gan RY, Wang YF, Cai SX, Xu XY, Zhang PZ, Li HB (2019) Effects and mechanisms of tea for the prevention and management of diabetes mellitus and diabetic complications: an updated review. Antioxidants. https://doi.org/10.3390/antiox8060170 CrossRefPubMedPubMedCentral

4.

Joshi T, Singh AK, Haratipour P, Sah AN, Pandey AK, Naseri R, Juyal V, Farzaei MH (2019) Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. J Cell Physiol 234(10):17212–17231. https://doi.org/10.1002/jcp.28528 CrossRefPubMed

5.

Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, Zi ZG, Zhao HH, Yang Y, Yu JQ (2018) Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother Biomedecine pharmacotherapie 101:510–527. https://doi.org/10.1016/j.biopha.2018.02.105 CrossRefPubMed

6.

Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 48(12):2460–2469. https://doi.org/10.1007/s00125-005-0023-4 CrossRefPubMed

7.

Dybjer E, Nilsson PM, Engstrom G, Helmer C, Nagga K (2018) Pre-diabetes and diabetes are independently associated with adverse cognitive test results: a cross-sectional, population-based study. BMC Endocr Disord 18(1):91. https://doi.org/10.1186/s12902-018-0318-3 CrossRefPubMedPubMedCentral

8.

Wennberg AMV, Hagen CE, Gottesman RF, Zipunnikov V, Kaufmann CN, Albert MS, Rebok GW, Kasper JD, Spira AP (2017) Longitudinal association between diabetes and cognitive decline: the National Health and Aging Trends Study. Arch Gerontol Geriatr 72:39–44. https://doi.org/10.1016/j.archger.2017.05.005 CrossRefPubMedPubMedCentral

9.

Infante-Garcia C, Jose Ramos-Rodriguez J, Marin-Zambrana Y, Teresa Fernandez-Ponce M, Casas L, Mantell C, Garcia-Alloza M (2017) Mango leaf extract improves central pathology and cognitive impairment in a type 2 diabetes mouse model. Brain Pathol 27(4):499–507. https://doi.org/10.1111/bpa.12433 CrossRefPubMed

10.

Ferrier J, Saleem A, Carter Ramirez A, Liu R, Chen E, Pesek T, Cal V, Balick M, Arnason JT (2018) Traditional medicines used by Q’eqchi’ Maya to treat diabetic symptoms and their antiglycation potential. J Ethnopharmacol 224:504–511. https://doi.org/10.1016/j.jep.2018.06.031 CrossRefPubMed

11.

Gorzynik-Debicka M, Przychodzen P, Cappello F, Kuban-Jankowska A, Marino Gammazza A, Knap N, Wozniak M, Gorska-Ponikowska M (2018) Potential health benefits of olive oil and plant polyphenols. Int J Mol Sci. https://doi.org/10.3390/ijms19030686 CrossRefPubMedPubMedCentral

12.

AlMatar M, Islam MR, Albarri O, Var I, Koksal F (2018) Pomegranate as a possible treatment in reducing risk of developing wound healing, obesity, neurodegenerative disorders, and diabetes mellitus. Mini Rev Med Chem 18(6):507–526. https://doi.org/10.2174/1389557517666170419114722 CrossRefPubMed

13.

Silveira AC, Dias JP, Santos VM, Oliveira PF, Alves MG, Rato L, Silva BM (2018) The action of polyphenols in Diabetes Mellitus and Alzheimer’s disease: a common agent for overlapping pathologies. Curr Neuropharmacol. https://doi.org/10.2174/1570159x16666180803162059 CrossRef

14.

Simo R, Ciudin A, Simo-Servat O, Hernandez C (2017) Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—the diabetologist’s perspective. Acta Diabetol 54(5):417–424. https://doi.org/10.1007/s00592-017-0970-5 CrossRefPubMed

15.

Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5(1):64–74. https://doi.org/10.1016/S1474-4422(05)70284-2 CrossRefPubMed

16.

Twig G, Gluzman I, Tirosh A, Gerstein HC, Yaniv G, Afek A, Derazne E, Tzur D, Karasik A, Gordon B, Fruchter E, Lubin G, Rudich A, Cukierman-Yaffe T (2014) Cognitive function and the risk for diabetes among young men. Diabetes Care 37(11):2982–2988. https://doi.org/10.2337/dc14-0715 CrossRefPubMed

17.

Kuo SC, Lai SW, Hung HC, Muo CH, Hung SC, Liu LL, Chang CW, Hwu YJ, Chen SL, Sung FC (2015) Association between comorbidities and dementia in diabetes mellitus patients: population-based retrospective cohort study. J Diabetes Complicat 29(8):1071–1076. https://doi.org/10.1016/j.jdiacomp.2015.06.010 CrossRef

18.

Crane PK, Walker R, Larson EB (2013) Glucose levels and risk of dementia. N Engl J Med 369(19):1863–1864. https://doi.org/10.1056/NEJMc1311765 CrossRefPubMed

19.

Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, Munch G, Wood AG, Forbes J, Greenaway TM, Pearson S, Srikanth V (2013) Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 36(12):4036–4042. https://doi.org/10.2337/dc13-0143 CrossRefPubMedPubMedCentral

20.

Li W, Huang E (2016) An update on type 2 diabetes mellitus as a risk factor for dementia. J Alzheimers Dis JAD 53(2):393–402. https://doi.org/10.3233/jad-160114 CrossRefPubMed

21.

Albai O, Frandes M, Timar R, Roman D, Timar B (2019) Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment. Neuropsychiatr Dis Treat 15:167–175. https://doi.org/10.2147/NDT.S189905 CrossRefPubMedPubMedCentral

22.

Wijesekara N, Goncalves RA, De Felice FG, Fraser PE (2018) Impaired peripheral glucose homeostasis and Alzheimer’s disease. Neuropharmacology 136(Pt B):172–181. https://doi.org/10.1016/j.neuropharm.2017.11.027 CrossRefPubMed

23.

Vetri F, Chavez R, Xu HL, Paisansathan C, Pelligrino DA (2013) Complex modulation of the expression of PKC isoforms in the rat brain during chronic type 1 diabetes mellitus. Brain Res 1490:202–209. https://doi.org/10.1016/j.brainres.2012.10.032 CrossRefPubMed

24.

Patino-Fernandez AM, Delamater AM, Applegate EB, Brady E, Eidson M, Nemery R, Gonzalez-Mendoza L, Richton S (2010) Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes 11(6):424–430. https://doi.org/10.1111/j.1399-5448.2009.00618.x CrossRefPubMedPubMedCentral

25.

Rao R, Nashawaty M, Fatima S, Ennis K, Tkac I (2018) Neonatal hyperglycemia alters the neurochemical profile, dendritic arborization and gene expression in the developing rat hippocampus. NMR Biomed 31(5):e3910. https://doi.org/10.1002/nbm.3910 CrossRefPubMedPubMedCentral

26.

Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37(1):67–76. https://doi.org/10.1016/j.nbd.2009.09.008 CrossRefPubMed

27.

Yaribeygi H, Atkin SL, Sahebkar A (2018) Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function. J Cell Physiol. https://doi.org/10.1002/jcp.27754 CrossRefPubMed

28.

Prasad S, Sajja RK, Naik P, Cucullo L (2014) Diabetes mellitus and blood-brain barrier dysfunction: an overview. J Pharmacovigil 2(2):125. https://doi.org/10.4172/2329-6887.1000125 CrossRefPubMedPubMedCentral

29.

Geijselaers SLC, Sep SJS, Claessens D, Schram MT, van Boxtel MPJ, Henry RMA, Verhey FRJ, Kroon AA, Dagnelie PC, Schalkwijk CG, van der Kallen CJH, Biessels GJ, Stehouwer CDA (2017) The role of hyperglycemia, insulin resistance, and blood pressure in diabetes-associated differences in cognitive performance—the Maastricht study. Diabetes Care 40(11):1537–1547. https://doi.org/10.2337/dc17-0330 CrossRefPubMed

30.

Dominguez LJ, Paolisso G, Barbagallo M (2010) Glucose control in the older patient: from intensive, to effective and safe. Aging Clin Exp Res 22(4):274–280. https://doi.org/10.3275/6629 CrossRefPubMed

31.

McNay EC, Cotero VE (2010) Mini-review: impact of recurrent hypoglycemia on cognitive and brain function. Physiol Behav 100(3):234–238. https://doi.org/10.1016/j.physbeh.2010.01.004 CrossRefPubMedPubMedCentral

32.

Chu X, Zhao Y, Liu F, Mi Y, Shen J, Wang X, Liu J, Jin W (2014) Rapidly raise blood sugar will aggravate brain damage after severe hypoglycemia in rats. Cell Biochem Biophys 69(1):131–139. https://doi.org/10.1007/s12013-013-9779-1 CrossRefPubMed

33.

Martin-Timon I, Del Canizo-Gomez FJ (2015) Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes 6(7):912–926. https://doi.org/10.4239/wjd.v6.i7.912 CrossRefPubMedPubMedCentral

34.

Rehni AK, Shukla V, Perez-Pinzon MA, Dave KR (2018) Acidosis mediates recurrent hypoglycemia-induced increase in ischemic brain injury in treated diabetic rats. Neuropharmacology 135:192–201. https://doi.org/10.1016/j.neuropharm.2018.03.016 CrossRefPubMedPubMedCentral

35.

He J, Ryder AG, Li S, Liu W, Zhu X (2018) Glycemic extremes are related to cognitive dysfunction in children with type 1 diabetes: a meta-analysis. J Diabetes Investig 9(6):1342–1353. https://doi.org/10.1111/jdi.12840 CrossRefPubMedPubMedCentral

36.

Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, Strotmeyer ES, Shorr RI, Metti A, Schwartz AV, Health ABCS (2013) Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 173(14):1300–1306. https://doi.org/10.1001/jamainternmed.2013.6176 CrossRefPubMedPubMedCentral

37.

Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T, Seaquist ER, Ismail-Beigi F, Sullivan MD, Lovato LC, Bergenstal RM, Gerstein HC, Investigators AGo, Investigators A-M, (2012) Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 35(4):787–793. https://doi.org/10.2337/dc11-1855 CrossRefPubMedPubMedCentral

38.

Ryan CM, Klein BEK, Lee KE, Cruickshanks KJ, Klein R (2016) Associations between recent severe hypoglycemia, retinal vessel diameters, and cognition in adults with type 1 diabetes. J Diabetes Complicat 30(8):1513–1518. https://doi.org/10.1016/j.jdiacomp.2016.08.010 CrossRef

39.

Zemva J, Schubert M (2014) The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer’s disease: possible therapeutic implications. CNS Neurol Disord Drug Targets 13(2):322–337CrossRefPubMed

40.

Banks WA, During MJ, Niehoff ML (2004) Brain uptake of the glucagon-like peptide-1 antagonist exendin (9–39) after intranasal administration. J Pharmacol Exp Ther 309(2):469–475. https://doi.org/10.1124/jpet.103.063222 CrossRefPubMed

41.

Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis JAD 8(3):247–268CrossRefPubMed

42.

Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH (2002) Ageing and diabetes: implications for brain function. Eur J Pharmacol 441(1–2):1–14CrossRefPubMed

43.

Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 423(6938):435–439. https://doi.org/10.1038/nature01640 CrossRefPubMed

44.

Callisaya M, Nosaka K (2017) Effects of exercise on type 2 diabetes mellitus-related cognitive impairment and dementia. J Alzheimers Dis JAD 59(2):503–513. https://doi.org/10.3233/JAD-161154 CrossRefPubMed

45.

Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci Off J Soc Neurosci 24(49):11120–11126. https://doi.org/10.1523/JNEUROSCI.2860-04.2004 CrossRef

46.

Yamamoto N, Ishikuro R, Tanida M, Suzuki K, Ikeda-Matsuo Y, Sobue K (2018) Insulin-signaling pathway regulates the degradation of amyloid beta-protein via astrocytes. Neuroscience 385:227–236. https://doi.org/10.1016/j.neuroscience.2018.06.018 CrossRefPubMed

47.

Hishikawa N, Yamashita T, Deguchi K, Wada J, Shikata K, Makino H, Abe K (2015) Cognitive and affective functions in diabetic patients associated with diabetes-related factors, white matter abnormality and aging. Eur J Neurol 22(2):313–321. https://doi.org/10.1111/ene.12568 CrossRefPubMed

48.

Neergaard JS, Dragsbaek K, Christiansen C, Nielsen HB, Brix S, Karsdal MA, Henriksen K (2017) Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain? Diabetes 66(7):1957–1963. https://doi.org/10.2337/db16-1444 CrossRefPubMed

49.

Geijselaers SLC, Sep SJS, Schram MT, van Boxtel MPJ, Henry RMA, Verhey FRJ, Kroon AA, Schaper NC, Dagnelie PC, van der Kallen CJH, Stehouwer CDA, Biessels GJ (2017) Insulin resistance and cognitive performance in type 2 diabetes—The Maastricht study. J Diabetes Complicat 31(5):824–830. https://doi.org/10.1016/j.jdiacomp.2017.01.020 CrossRef

50.

Kalmijn S, Janssen JA, Pols HA, Lamberts SW, Breteler MM (2000) A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J Clin Endocrinol Metab 85(12):4551–4555. https://doi.org/10.1210/jcem.85.12.7033 CrossRefPubMed

51.

Holmes C (2013) Review: systemic inflammation and Alzheimer’s disease. Neuropathol Appl Neurobiol 39(1):51–68. https://doi.org/10.1111/j.1365-2990.2012.01307.x CrossRefPubMed

52.

McCusker RH, Kelley KW (2013) Immune-neural connections: how the immune system’s response to infectious agents influences behavior. J Exp Biol 216(Pt 1):84–98. https://doi.org/10.1242/jeb.073411 CrossRefPubMedPubMedCentral

53.

Janelidze S, Hertze J, Nagga K, Nilsson K, Nilsson C, Swedish Bio FSG, Wennstrom M, van Westen D, Blennow K, Zetterberg H, Hansson O (2017) Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging 51:104–112. https://doi.org/10.1016/j.neurobiolaging.2016.11.017 CrossRefPubMedPubMedCentral

54.

Dhanda S, Sandhir R (2018) Blood–brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins. Mol Neurobiol 55(5):3642–3659. https://doi.org/10.1007/s12035-017-0521-7 CrossRefPubMed

55.

Nadeau S, Rivest S (2000) Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J Neurosci Off J Soc Neurosci 20(9):3456–3468CrossRef

56.

Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59(3):710–713. https://doi.org/10.2337/db09-1163 CrossRefPubMed

57.

Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M, Loba J (2016) Adiponectin, leptin and IL-1 beta in elderly diabetic patients with mild cognitive impairment. Metab Brain Dis 31(2):257–266. https://doi.org/10.1007/s11011-015-9739-0 CrossRefPubMed

58.

Lavielle P, Talavera JO, Reynoso N, Gonzalez M, Gomez-Diaz RA, Cruz M, Vazquez F, Wacher NH, Group DS (2015) Prevalence of cognitive impairment in recently diagnosed type 2 diabetes patients: are chronic inflammatory diseases responsible for cognitive decline? PLoS One 10(10):e0141325CrossRefPubMedPubMedCentral

59.

Feinkohl I, Price JF, Strachan MW, Frier BM (2015) The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. Alzheimers Res Ther 7(1):46. https://doi.org/10.1186/s13195-015-0130-5 CrossRefPubMedPubMedCentral

60.

McCrimmon RJ, Ryan CM, Frier BM (2012) Diabetes and cognitive dysfunction. Lancet 379(9833):2291–2299. https://doi.org/10.1016/S0140-6736(12)60360-2 CrossRefPubMed

61.

Naidu VV, Ismail K, Amiel S, Kohli R, Crosby-Nwaobi R, Sivaprasad S, Stewart R (2016) Associations between retinal markers of microvascular disease and cognitive impairment in newly diagnosed type 2 diabetes mellitus: a case control study. PLoS One 11(1):e0147160. https://doi.org/10.1371/journal.pone.0147160 CrossRefPubMedPubMedCentral

62.

Dalkara T, Gursoy-Ozdemir Y, Yemisci M (2011) Brain microvascular pericytes in health and disease. Acta Neuropathol 122(1):1–9. https://doi.org/10.1007/s00401-011-0847-6 CrossRefPubMed

63.

Feinkohl I, Keller M, Robertson CM, Morling JR, Williamson RM, Nee LD, McLachlan S, Sattar N, Welsh P, Reynolds RM, Russ TC, Deary IJ, Strachan MW, Price JF (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36(9):2779–2786CrossRefPubMedPubMedCentral

64.

Marioni RE, Deary IJ, Strachan MW, Lowe GD, Rumley A, Murray GD, Price JF (2010) Blood rheology and cognition in the Edinburgh Type 2 Diabetes Study. Age Ageing 39(3):354–359. https://doi.org/10.1093/ageing/afq021 CrossRefPubMed

65.

Weller RO, Massey A, Kuo YM, Roher AE (2000) Cerebral amyloid angiopathy: accumulation of A beta in interstitial fluid drainage pathways in Alzheimer’s disease. Ann N Y Acad Sci 903:110–117. https://doi.org/10.1111/j.1749-6632.2000.tb06356.x CrossRefPubMed

66.

Andero R, Choi DC, Ressler KJ (2014) BDNF-TrkB receptor regulation of distributed adult neural plasticity, memory formation, and psychiatric disorders. Prog Mol Biol Transl Sci 122:169–192. https://doi.org/10.1016/B978-0-12-420170-5.00006-4 CrossRefPubMed

67.

Mohammadi A, Amooeian VG, Rashidi E (2018) Dysfunction in brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, Parkinson’s and Alzheimer’s diseases. Curr Gene Ther 18(1):45–63. https://doi.org/10.2174/1566523218666180302163029 CrossRefPubMed

68.

Yan T, Xu M, Wan S, Wang M, Wu B, Xiao F, Bi K, Jia Y (2016) Schisandra chinensis produces the antidepressant-like effects in repeated corticosterone-induced mice via the BDNF/TrkB/CREB signaling pathway. Psychiatry Res 243:135–142. https://doi.org/10.1016/j.psychres.2016.06.037 CrossRefPubMed

69.

Tao W, Dong Y, Su Q, Wang H, Chen Y, Xue W, Chen C, Xia B, Duan J, Chen G (2016) Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway. Behav Brain Res 308:177–186. https://doi.org/10.1016/j.bbr.2016.04.039 CrossRefPubMed

70.

Chen W, Liang T, Zuo W, Wu X, Shen Z, Wang F, Li C, Zheng Y, Peng G (2018) Neuroprotective effect of 1-deoxynojirimycin on cognitive impairment, beta-amyloid deposition, and neuroinflammation in the SAMP8 mice. Biomed Pharmacother Biomedecine pharmacotherapie 106:92–97. https://doi.org/10.1016/j.biopha.2018.06.106 CrossRefPubMed

71.

Tang L, Kang YT, Yin B, Sun LJ, Fan XS (2017) Effects of weight-bearing ladder and aerobic treadmill exercise on learning and memory ability of diabetic rats and its mechanism. Zhongguo ying yong sheng li xue za zhi Zhongguo yingyong shenglixue zazhi Chin J Appl Physiol 33(5):436–440. https://doi.org/10.12047/j.cjap.5570.2017.105 CrossRef

72.

Luo H, Xiang Y, Qu X, Liu H, Liu C, Li G, Han L, Qin X (2019) Apelin-13 suppresses neuroinflammation against cognitive deficit in a streptozotocin-induced rat model of Alzheimer’s disease through activation of BDNF-TrkB signaling pathway. Front Pharmacol 10:395. https://doi.org/10.3389/fphar.2019.00395 CrossRefPubMedPubMedCentral

73.

Zirpel L, Janowiak MA, Veltri CA, Parks TN (2000) AMPA receptor-mediated, calcium-dependent CREB phosphorylation in a subpopulation of auditory neurons surviving activity deprivation. J Neurosci Off J Soc Neurosci 20(16):6267–6275CrossRef

74.

Srivastava P, Dhuriya YK, Kumar V, Srivastava A, Gupta R, Shukla RK, Yadav RS, Dwivedi HN, Pant AB, Khanna VK (2018) PI3K/Akt/GSK3beta induced CREB activation ameliorates arsenic mediated alterations in NMDA receptors and associated signaling in rat hippocampus: neuroprotective role of curcumin. Neurotoxicology 67:190–205. https://doi.org/10.1016/j.neuro.2018.04.018 CrossRefPubMed

75.

Wang Y, Zhang J, Han M, Liu B, Gao Y, Ma P, Zhang S, Zheng Q, Song X (2016) SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol 54(10):1982–1990. https://doi.org/10.3109/13880209.2015.1137951 CrossRefPubMed

76.

Bathina S, Das UN (2015) Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci AMS 11(6):1164–1178. https://doi.org/10.5114/aoms.2015.56342 CrossRefPubMed

77.

Zhou X, Wang S, Ding X, Qin L, Mao Y, Chen L, Li W, Ying C (2017) Zeaxanthin improves diabetes-induced cognitive deficit in rats through activiting PI3K/AKT signaling pathway. Brain Res Bull 132:190–198. https://doi.org/10.1016/j.brainresbull.2017.06.001 CrossRefPubMed

78.

Xiang Q, Zhang J, Li CY, Wang Y, Zeng MJ, Cai ZX, Tian RB, Jia W, Li XH (2015) Insulin resistance-induced hyperglycemia decreased the activation of Akt/CREB in hippocampus neurons: molecular evidence for mechanism of diabetes-induced cognitive dysfunction. Neuropeptides 54:9–15. https://doi.org/10.1016/j.npep.2015.08.009 CrossRefPubMed

79.

John CM, Mohamed Yusof NIS, Abdul Aziz SH, Mohd Fauzi F (2018) Maternal cognitive impairment associated with gestational diabetes mellitus—a review of potential contributing mechanisms. Int J Mol Sci. https://doi.org/10.3390/ijms19123894 CrossRefPubMedPubMedCentral

80.

Jiang B, Xiong Z, Yang J, Wang W, Wang Y, Hu ZL, Wang F, Chen JG (2012) Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br J Pharmacol 166(6):1872–1887. https://doi.org/10.1111/j.1476-5381.2012.01902.x CrossRefPubMedPubMedCentral

81.

Zhang Y, Shao F, Wang Q, Xie X, Wang W (2017) Neuroplastic correlates in the mPFC underlying the impairment of stress-coping ability and cognitive flexibility in adult rats exposed to chronic mild stress during adolescence. Neural Plast 2017:9382797. https://doi.org/10.1155/2017/9382797 CrossRefPubMedPubMedCentral

82.

Yuan S, Jiang X, Zhou X, Zhang Y, Teng T, Xie P (2018) Inosine alleviates depression-like behavior and increases the activity of the ERK-CREB signaling in adolescent male rats. Neuroreport. https://doi.org/10.1097/wnr.0000000000001101 CrossRefPubMedPubMedCentral

83.

Liu P, Zou L, Jiao Q, Chi T, Ji X, Qi Y, Xu Q, Wang L (2013) Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. Neurosci Lett 543:115–120. https://doi.org/10.1016/j.neulet.2013.02.065 CrossRefPubMed

84.

Liu D, Xie K, Yang X, Gu J, Ge L, Wang X, Wang Z (2014) Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats. Behav Brain Res 264:9–16. https://doi.org/10.1016/j.bbr.2014.01.039 CrossRefPubMed

85.

Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K, Yamaguchi A, Takai T, Kodama T, Chatila TA, Bito H, Takayanagi H (2006) Regulation of osteoclast differentiation and function by the CaMK–CREB pathway. Nat Med 12(12):1410–1416. https://doi.org/10.1038/nm1515 CrossRefPubMed

86.

Bossuyt J, Bers DM (2013) Visualizing CaMKII and CaM activity: a paradigm of compartmentalized signaling. J Mol Med 91(8):907–916. https://doi.org/10.1007/s00109-013-1060-y CrossRefPubMed

87.

Wei F, Qiu CS, Liauw J, Robinson DA, Ho N, Chatila T, Zhuo M (2002) Calcium calmodulin-dependent protein kinase IV is required for fear memory. Nat Neurosci 5(6):573–579. https://doi.org/10.1038/nn855 CrossRefPubMed

88.

Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, Ho L, Wang J, Yemul S, Barnum S, Bilski A, Gong BY, Pasinetti GM (2013) IVIG immunotherapy protects against synaptic dysfunction in Alzheimer’s disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Mol Immunol 56(4):619–629. https://doi.org/10.1016/j.molimm.2013.06.016 CrossRefPubMed

89.

Yan X, Liu J, Ye Z, Huang J, He F, Xiao W, Hu X, Luo Z (2016) CaMKII-mediated CREB phosphorylation is involved in Ca²⁺-induced BDNF mRNA transcription and neurite outgrowth promoted by electrical stimulation. PLoS One 11(9):e0162784. https://doi.org/10.1371/journal.pone.0162784 CrossRefPubMedPubMedCentral

90.

Gomez-Pinilla F, Ying Z, Zhuang Y (2012) Brain and spinal cord interaction: protective effects of exercise prior to spinal cord injury. PLoS One 7(2):e32298. https://doi.org/10.1371/journal.pone.0032298 CrossRefPubMedPubMedCentral

91.

Zhang G, Fang H, Li Y, Xu J, Zhang D, Sun Y, Zhou L, Zhang H (2019) Neuroprotective effect of astragalus polysacharin on streptozotocin (STZ)-induced diabetic rats. Med Sci Mon Int Med J Exp Clin Res 25:135–141. https://doi.org/10.12659/MSM.912213 CrossRef

92.

Cui W, Bai Y, Luo P, Miao L, Cai L (2013) Preventive and therapeutic effects of MG132 by activating Nrf2–ARE signaling pathway on oxidative stress-induced cardiovascular and renal injury. Oxid Med Cell longev 2013:306073. https://doi.org/10.1155/2013/306073 CrossRefPubMedPubMedCentral

93.

Song Y, Ding W, Bei Y, Xiao Y, Tong HD, Wang LB, Ai LY (2018) Insulin is a potential antioxidant for diabetes-associated cognitive decline via regulating Nrf2 dependent antioxidant enzymes. Biomed Pharmacother Biomedecine pharmacotherapie 104:474–484. https://doi.org/10.1016/j.biopha.2018.04.097 CrossRefPubMed

94.

Zhang S, Yuan L, Zhang L, Li C, Li J (2018) Prophylactic use of troxerutin can delay the development of diabetic cognitive dysfunction and improve the expression of Nrf2 in the hippocampus on STZ diabetic rats. Behav Neurol 2018:8678539. https://doi.org/10.1155/2018/8678539 CrossRefPubMedPubMedCentral

95.

Feng Y, Chu A, Luo Q, Wu M, Shi X, Chen Y (2018) The protective effect of astaxanthin on cognitive function via inhibition of oxidative stress and inflammation in the brains of chronic T2DM rats. Front Pharmacol 9:748. https://doi.org/10.3389/fphar.2018.00748 CrossRefPubMedPubMedCentral

96.

McNeilly AD, Gallagher JR, Dinkova-Kostova AT, Hayes JD, Sharkey J, Ashford ML, McCrimmon RJ (2016) Nrf2-mediated neuroprotection against recurrent hypoglycemia is insufficient to prevent cognitive impairment in a rodent model of type 1 diabetes. Diabetes 65(10):3151–3160. https://doi.org/10.2337/db15-1653 CrossRefPubMed

97.

Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer’s Disease Study G (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenom J 6(4):246–254. https://doi.org/10.1038/sj.tpj.6500369 CrossRef

98.

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis JAD 44(3):897–906. https://doi.org/10.3233/JAD-141791 CrossRefPubMed

99.

Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P (2013) Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discov Med 16(90):277–286PubMed

100.

Moosavi F, Hosseini R, Saso L, Firuzi O (2016) Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Dev Ther 10:23–42. https://doi.org/10.2147/DDDT.S96936 CrossRef

101.

Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG (2014) Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review. Biochem Pharmacol 92(1):73–89. https://doi.org/10.1016/j.bcp.2014.07.018 CrossRefPubMedPubMedCentral

102.

Ali F, Siddique Y (2019) Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease. CNS Neurol Disord Drug Targets. https://doi.org/10.2174/1871527318666190319141835 CrossRefPubMed

103.

Nabavi SF, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wozniak K, Nabavi SM (2015) Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull 119(Pt A):1–11. https://doi.org/10.1016/j.brainresbull.2015.09.002 CrossRefPubMed

104.

Lin CW, Wu MJ, Liu IY, Su JD, Yen JH (2010) Neurotrophic and cytoprotective action of luteolin in PC12 cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J Agric Food Chem 58(7):4477–4486. https://doi.org/10.1021/jf904061x CrossRefPubMed

105.

Hu LW, Yen JH, Shen YT, Wu KY, Wu MJ (2014) Luteolin modulates 6-hydroxydopamine-induced transcriptional changes of stress response pathways in PC12 cells. PLoS One 9(5):e97880. https://doi.org/10.1371/journal.pone.0097880 CrossRefPubMedPubMedCentral

106.

Tsai FS, Peng WH, Wang WH, Wu CR, Hsieh CC, Lin YT, Feng IC, Hsieh MT (2007) Effects of luteolin on learning acquisition in rats: involvement of the central cholinergic system. Life Sci 80(18):1692–1698. https://doi.org/10.1016/j.lfs.2007.01.055 CrossRefPubMed

107.

Liu Y, Tian X, Gou L, Sun L, Ling X, Yin X (2013) Luteolin attenuates diabetes-associated cognitive decline in rats. Brain Res Bull 94:23–29. https://doi.org/10.1016/j.brainresbull.2013.02.001 CrossRefPubMed

108.

Liu Y, Fu X, Lan N, Li S, Zhang J, Wang S, Li C, Shang Y, Huang T, Zhang L (2014) Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behav Brain Res 267:178–188. https://doi.org/10.1016/j.bbr.2014.02.040 CrossRefPubMed

109.

Lall RK, Adhami VM, Mukhtar H (2016) Dietary flavonoid fisetin for cancer prevention and treatment. Mol Nutr Food Res 60(6):1396–1405. https://doi.org/10.1002/mnfr.201600025 CrossRefPubMedPubMedCentral

110.

Prasath GS, Sundaram CS, Subramanian SP (2013) Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rats. Endocrine 44(2):359–368. https://doi.org/10.1007/s12020-012-9866-x CrossRefPubMed

111.

Zhen L, Zhu J, Zhao X, Huang W, An Y, Li S, Du X, Lin M, Wang Q, Xu Y, Pan J (2012) The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system. Behav Brain Res 228(2):359–366. https://doi.org/10.1016/j.bbr.2011.12.017 CrossRefPubMed

112.

Prasath GS, Subramanian SP (2014) Antihyperlipidemic effect of fisetin, a bioflavonoid of strawberries, studied in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 28(10):442–449. https://doi.org/10.1002/jbt.21583 CrossRefPubMed

113.

Krasieva TB, Ehren J, O’Sullivan T, Tromberg BJ, Maher P (2015) Cell and brain tissue imaging of the flavonoid fisetin using label-free two-photon microscopy. Neurochem Int 89:243–248. https://doi.org/10.1016/j.neuint.2015.08.003 CrossRefPubMedPubMedCentral

114.

Maher P (2009) Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr 4(4):297–307. https://doi.org/10.1007/s12263-009-0142-5 CrossRefPubMedPubMedCentral

115.

Currais A, Farrokhi C, Dargusch R, Armando A, Quehenberger O, Schubert D, Maher P (2018) Fisetin reduces the impact of aging on behavior and physiology in the rapidly aging SAMP8 mouse. J Gerontol Ser A Biol Sci Med Sci 73(3):299–307. https://doi.org/10.1093/gerona/glx104 CrossRef

116.

Sandireddy R, Yerra VG, Komirishetti P, Areti A, Kumar A (2016) Fisetin imparts neuroprotection in experimental diabetic neuropathy by modulating Nrf2 and NF-kappaB pathways. Cell Mol Neurobiol 36(6):883–892. https://doi.org/10.1007/s10571-015-0272-9 CrossRefPubMed

117.

Zhao X, Li XL, Liu X, Wang C, Zhou DS, Ma Q, Zhou WH, Hu ZY (2015) Antinociceptive effects of fisetin against diabetic neuropathic pain in mice: engagement of antioxidant mechanisms and spinal GABAA receptors. Pharmacol Res 102:286–297. https://doi.org/10.1016/j.phrs.2015.10.007 CrossRefPubMed

118.

Kasi PD, Tamilselvam R, Skalicka-Wozniak K, Nabavi SF, Daglia M, Bishayee A, Pazoki-Toroudi H, Nabavi SM (2016) Molecular targets of curcumin for cancer therapy: an updated review. Tumour Biol J Int Soc Oncodev Biol Med 37(10):13017–13028. https://doi.org/10.1007/s13277-016-5183-y CrossRef

119.

Platania CBM, Fidilio A, Lazzara F, Piazza C, Geraci F, Giurdanella G, Leggio GM, Salomone S, Drago F, Bucolo C (2018) Retinal protection and distribution of curcumin in vitro and in vivo. Front Pharmacol 9:670. https://doi.org/10.3389/fphar.2018.00670 CrossRefPubMedPubMedCentral

120.

Koo BB, Calderazzo S, Bowley BGE, Kolli A, Moss MB, Rosene DL, Moore TL (2018) Long-term effects of curcumin in the non-human primate brain. Brain Res Bull 142:88–95. https://doi.org/10.1016/j.brainresbull.2018.06.015 CrossRefPubMedPubMedCentral

121.

Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M, Kumar S, Wang R, Pradeepkiran JA, Ogunmokun G, Thamarai K, Quesada K, Boles A, Reddy AP (2018) Protective effects of indian spice curcumin against amyloid-beta in Alzheimer’s disease. J Alzheimers Dis JAD 61(3):843–866. https://doi.org/10.3233/JAD-170512 CrossRefPubMed

122.

Zhang L, Fang Y, Xu Y, Lian Y, Xie N, Wu T, Zhang H, Sun L, Zhang R, Wang Z (2015) Curcumin improves amyloid beta-peptide (1–42) induced spatial memory deficits through BDNF–ERK signaling pathway. PLoS One 10(6):e0131525. https://doi.org/10.1371/journal.pone.0131525 CrossRefPubMedPubMedCentral

123.

Faheem NM, El Askary A (2017) Neuroprotective role of curcumin on the hippocampus against the structural and serological alterations of streptozotocin-induced diabetes in Sprague Dawely rats. Iran J Basic Med Sci 20(6):690–699. https://doi.org/10.22038/IJBMS.2017.8839 CrossRefPubMedPubMedCentral

124.

Kumar PT, George N, Antony S, Paulose CS (2013) Curcumin restores diabetes induced neurochemical changes in the brain stem of Wistar rats. Eur J Pharmacol 702(1–3):323–331. https://doi.org/10.1016/j.ejphar.2013.01.012 CrossRefPubMed

125.

Kumar TP, Antony S, Gireesh G, George N, Paulose CS (2010) Curcumin modulates dopaminergic receptor, CREB and phospholipase C gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats. J Biomed Sci 17:43. https://doi.org/10.1186/1423-0127-17-43 CrossRefPubMedPubMedCentral

126.

Kuhad A, Chopra K (2007) Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 576(1–3):34–42. https://doi.org/10.1016/j.ejphar.2007.08.001 CrossRefPubMed

127.

Cox KH, Pipingas A, Scholey AB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29(5):642–651. https://doi.org/10.1177/0269881114552744 CrossRefPubMed

128.

Rainey-Smith SR, Brown BM, Sohrabi HR, Shah T, Goozee KG, Gupta VB, Martins RN (2016) Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr 115(12):2106–2113. https://doi.org/10.1017/S0007114516001203 CrossRefPubMed

129.

Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, Martinez J, Wong KP, Liu J, Merrill DA, Chen ST, Henning SM, Satyamurthy N, Huang SC, Heber D, Barrio JR (2018) Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry 26(3):266–277. https://doi.org/10.1016/j.jagp.2017.10.010 CrossRef

130.

Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G (2019) The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr 11:41. https://doi.org/10.1186/s13098-019-0437-7 CrossRefPubMedPubMedCentral

131.

Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58(3):516–527. https://doi.org/10.1002/mnfr.201300724 CrossRefPubMed

132.

Kulkarni SS, Canto C (2015) The molecular targets of resveratrol. Biochem Biophys Acta 1852(6):1114–1123. https://doi.org/10.1016/j.bbadis.2014.10.005 CrossRefPubMed

133.

Tian Z, Wang J, Xu M, Wang Y, Zhang M, Zhou Y (2016) Resveratrol improves cognitive impairment by regulating apoptosis and synaptic plasticity in streptozotocin-induced diabetic rats. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 40(6):1670–1677. https://doi.org/10.1159/000453216 CrossRef

134.

Gocmez SS, Sahin TD, Yazir Y, Duruksu G, Eraldemir FC, Polat S, Utkan T (2018) Resveratrol prevents cognitive deficits by attenuating oxidative damage and inflammation in rat model of streptozotocin diabetes induced vascular dementia. Physiol Behav. https://doi.org/10.1016/j.physbeh.2018.12.012 CrossRefPubMed

135.

Sadi G, Konat D (2016) Resveratrol regulates oxidative biomarkers and antioxidant enzymes in the brain of streptozotocin-induced diabetic rats. Pharm Biol 54(7):1156–1163. https://doi.org/10.3109/13880209.2015.1056311 CrossRefPubMed

136.

Thomas J, Garg ML, Smith DW (2014) Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice. J Nutr Biochem 25(3):313–318. https://doi.org/10.1016/j.jnutbio.2013.11.005 CrossRefPubMed

137.

Huber JD (2008) Diabetes, cognitive function, and the blood–brain barrier. Curr Pharm Des 14(16):1594–1600CrossRefPubMed

138.

Jing YH, Chen KH, Kuo PC, Pao CC, Chen JK (2013) Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol. Neuroendocrinology 98(2):116–127. https://doi.org/10.1159/000350435 CrossRefPubMed

139.

Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Correa M, da Rosa MM, Rubin MA, Chitolina Schetinger MR, Morsch VM (2009) Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 610(1–3):42–48. https://doi.org/10.1016/j.ejphar.2009.03.032 CrossRefPubMed

140.

Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Maldonado PA, Correa M, da Rosa CS, Becker L, Bagatini M, Goncalves JF, Jaques Jdos S, Schetinger MR, Morsch VM (2009) Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res Bull 80(6):371–376. https://doi.org/10.1016/j.brainresbull.2009.08.019 CrossRefPubMed

141.

Wong RH, Raederstorff D, Howe PR (2016) Acute resveratrol consumption improves neurovascular coupling capacity in adults with type 2 diabetes mellitus. Nutrients. https://doi.org/10.3390/nu8070425 CrossRefPubMedPubMedCentral

142.

Witte AV, Kerti L, Margulies DS, Floel A (2014) Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci Off J Soc Neurosci 34(23):7862–7870. https://doi.org/10.1523/JNEUROSCI.0385-14.2014 CrossRef

143.

Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. Cancer Lett 269(2):315–325. https://doi.org/10.1016/j.canlet.2008.03.046 CrossRefPubMed

144.

Xue F, Nie X, Shi J, Liu Q, Wang Z, Li X, Zhou J, Su J, Xue M, Chen WD, Wang YD (2017) Quercetin inhibits LPS-induced inflammation and ox-LDL-induced lipid deposition. Front Pharmacol 8:40. https://doi.org/10.3389/fphar.2017.00040 CrossRefPubMedPubMedCentral

145.

Fuentes J, Atala E, Pastene E, Carrasco-Pozo C, Speisky H (2017) Quercetin oxidation paradoxically enhances its antioxidant and cytoprotective properties. J Agric Food Chem 65(50):11002–11010. https://doi.org/10.1021/acs.jafc.7b05214 CrossRefPubMed

146.

Gormaz JG, Quintremil S, Rodrigo R (2015) Cardiovascular disease: a target for the pharmacological effects of quercetin. Curr Top Med Chem 15(17):1735–1742CrossRefPubMed

147.

Zunino S (2009) Type 2 diabetes and glycemic response to grapes or grape products. J Nutr 139(9):1794S–1800S. https://doi.org/10.3945/jn.109.107631 CrossRefPubMed

148.

Bhutada P, Mundhada Y, Bansod K, Bhutada C, Tawari S, Dixit P, Mundhada D (2010) Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats. Neurobiol Learn Mem 94(3):293–302. https://doi.org/10.1016/j.nlm.2010.06.008 CrossRefPubMed

149.

Tota S, Awasthi H, Kamat PK, Nath C, Hanif K (2010) Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209(1):73–79. https://doi.org/10.1016/j.bbr.2010.01.017 CrossRefPubMed

150.

Demir EA, Gergerlioglu HS, Oz M (2016) Antidepressant-like effects of quercetin in diabetic rats are independent of hypothalamic-pituitary-adrenal axis. Acta Neuropsychiatr 28(1):23–30. https://doi.org/10.1017/neu.2015.45 CrossRefPubMed

151.

Maciel RM, Carvalho FB, Olabiyi AA, Schmatz R, Gutierres JM, Stefanello N, Zanini D, Rosa MM, Andrade CM, Rubin MA, Schetinger MR, Morsch VM, Danesi CC, Lopes STA (2016) Neuroprotective effects of quercetin on memory and anxiogenic-like behavior in diabetic rats: role of ectonucleotidases and acetylcholinesterase activities. Biomed Pharmacother Biomedecine pharmacotherapie 84:559–568. https://doi.org/10.1016/j.biopha.2016.09.069 CrossRefPubMed

152.

Chougala MB, Bhaskar JJ, Rajan MG, Salimath PV (2012) Effect of curcumin and quercetin on lysosomal enzyme activities in streptozotocin-induced diabetic rats. Clin Nutr 31(5):749–755. https://doi.org/10.1016/j.clnu.2012.02.003 CrossRefPubMed

153.

Youl E, Bardy G, Magous R, Cros G, Sejalon F, Virsolvy A, Richard S, Quignard JF, Gross R, Petit P, Bataille D, Oiry C (2010) Quercetin potentiates insulin secretion and protects INS-1 pancreatic beta-cells against oxidative damage via the ERK1/2 pathway. Br J Pharmacol 161(4):799–814. https://doi.org/10.1111/j.1476-5381.2010.00910.x CrossRefPubMedPubMedCentral

154.

Coskun O, Kanter M, Korkmaz A, Oter S (2005) Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 51(2):117–123. https://doi.org/10.1016/j.phrs.2004.06.002 CrossRefPubMed

155.

Bournival J, Francoeur MA, Renaud J, Martinoli MG (2012) Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation, nitrosative stress, and apoptosis. Rejuvenation Res 15(3):322–333. https://doi.org/10.1089/rej.2011.1242 CrossRefPubMed

156.

Nakagawa T, Itoh M, Ohta K, Hayashi Y, Hayakawa M, Yamada Y, Akanabe H, Chikaishi T, Nakagawa K, Itoh Y, Muro T, Yanagida D, Nakabayashi R, Mori T, Saito K, Ohzawa K, Suzuki C, Li S, Ueda M, Wang MX, Nishida E, Islam S, Tana Kobori M, Inuzuka T (2016) Improvement of memory recall by quercetin in rodent contextual fear conditioning and human early-stage Alzheimer’s disease patients. NeuroReport 27(9):671–676. https://doi.org/10.1097/WNR.0000000000000594 CrossRefPubMed

157.

Broman-Fulks JJ, Canu WH, Trout KL, Nieman DC (2012) The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial. Ther Adv Psychopharmacol 2(4):131–138. https://doi.org/10.1177/2045125312445894 CrossRefPubMedPubMedCentral

158.

Venza I, Visalli M, Oteri R, Beninati C, Teti D, Venza M (2018) Genistein reduces proliferation of EP3-expressing melanoma cells through inhibition of PGE2-induced IL-8 expression. Int Immunopharmacol 62:86–95. https://doi.org/10.1016/j.intimp.2018.06.009 CrossRefPubMed

159.

Ganai AA, Farooqi H (2015) Bioactivity of genistein: a review of in vitro and in vivo studies. Biomed Pharmacother Biomedecine pharmacotherapie 76:30–38. https://doi.org/10.1016/j.biopha.2015.10.026 CrossRefPubMed

160.

Wang Y, Cai B, Shao J, Wang TT, Cai RZ, Ma CJ, Han T, Du J (2016) Genistein suppresses the mitochondrial apoptotic pathway in hippocampal neurons in rats with Alzheimer’s disease. Neural Regen Res 11(7):1153–1158. https://doi.org/10.4103/1673-5374.187056 CrossRefPubMedPubMedCentral

161.

Bonet-Costa V, Herranz-Perez V, Blanco-Gandia M, Mas-Bargues C, Ingles M, Garcia-Tarraga P, Rodriguez-Arias M, Minarro J, Borras C, Garcia-Verdugo JM, Vina J (2016) Clearing amyloid-beta through PPARgamma/ApoE activation by genistein is a treatment of experimental Alzheimer’s disease. J Alzheimers Dis JAD 51(3):701–711. https://doi.org/10.3233/JAD-151020 CrossRefPubMed

162.

Ye S, Wang TT, Cai B, Wang Y, Li J, Zhan JX, Shen GM (2017) Genistein protects hippocampal neurons against injury by regulating calcium/calmodulin dependent protein kinase IV protein levels in Alzheimer’s disease model rats. Neural Regen Res 12(9):1479–1484. https://doi.org/10.4103/1673-5374.215260 CrossRefPubMedPubMedCentral

163.

Rajput MS, Sarkar PD (2017) Modulation of neuro-inflammatory condition, acetylcholinesterase and antioxidant levels by genistein attenuates diabetes associated cognitive decline in mice. Chem Biol Interact 268:93–102. https://doi.org/10.1016/j.cbi.2017.02.021 CrossRefPubMed

164.

Zhang Z, Yan J, Shi H (2013) Hyperglycemia as a risk factor of ischemic stroke. J Drug Metab Toxicol. https://doi.org/10.4172/2157-7609.1000153 CrossRefPubMedPubMedCentral

165.

Rajput MS, Sarkar PD, Nirmal NP (2017) Inhibition of DPP-4 activity and neuronal atrophy with genistein attenuates neurological deficits induced by transient global cerebral ischemia and reperfusion in streptozotocin-induced diabetic mice. Inflammation 40(2):623–635. https://doi.org/10.1007/s10753-017-0509-5 CrossRefPubMed

166.

Liu YW, Zhu X, Yang QQ, Lu Q, Wang JY, Li HP, Wei YQ, Yin JL, Yin XX (2013) Suppression of methylglyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive decline in rats. Psychopharmacology 228(4):585–594. https://doi.org/10.1007/s00213-013-3061-5 CrossRefPubMed

167.

Marrazzo G, Bosco P, La Delia F, Scapagnini G, Di Giacomo C, Malaguarnera M, Galvano F, Nicolosi A, Li Volti G (2011) Neuroprotective effect of silibinin in diabetic mice. Neurosci Lett 504(3):252–256. https://doi.org/10.1016/j.neulet.2011.09.041 CrossRefPubMed

168.

Li R, Zang A, Zhang L, Zhang H, Zhao L, Qi Z, Wang H (2014) Chrysin ameliorates diabetes-associated cognitive deficits in Wistar rats. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(10):1527–1532. https://doi.org/10.1007/s10072-014-1784-7 CrossRef

169.

Jiang B, Le L, Pan H, Hu K, Xu L, Xiao P (2014) Dihydromyricetin ameliorates the oxidative stress response induced by methylglyoxal via the AMPK/GLUT4 signaling pathway in PC12 cells. Brain Res Bull 109:117–126. https://doi.org/10.1016/j.brainresbull.2014.10.010 CrossRefPubMed

170.

Sharifzadeh M, Ranjbar A, Hosseini A, Khanavi M (2017) The effect of green tea extract on oxidative stress and spatial learning in streptozotocin-diabetic rats. Iran J Pharm Res IJPR 16(1):201–209PubMed

171.

Baluchnejadmojarad T, Roghani M (2011) Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress. Behav Brain Res 224(2):305–310. https://doi.org/10.1016/j.bbr.2011.06.007 CrossRefPubMed

172.

El-Marasy SA, Abdallah HM, El-Shenawy SM, El-Khatib AS, El-Shabrawy OA, Kenawy SA (2014) Anti-depressant effect of hesperidin in diabetic rats. Can J Physiol Pharmacol 92(11):945–952. https://doi.org/10.1139/cjpp-2014-0281 CrossRefPubMed

173.

Ashafaq M, Varshney L, Khan MH, Salman M, Naseem M, Wajid S, Parvez S (2014) Neuromodulatory effects of hesperidin in mitigating oxidative stress in streptozotocin induced diabetes. Biomed Res Int 2014:249031. https://doi.org/10.1155/2014/249031 CrossRefPubMedPubMedCentral

174.

Pan Y, Hong Y, Zhang QY, Kong LD (2013) Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology 38(1):122–134. https://doi.org/10.1016/j.psyneuen.2012.05.007 CrossRefPubMed

175.

Ola MS, Aleisa AM, Al-Rejaie SS, Abuohashish HM, Parmar MY, Alhomida AS, Ahmed MM (2014) Flavonoid, morin inhibits oxidative stress, inflammation and enhances neurotrophic support in the brain of streptozotocin-induced diabetic rats. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(7):1003–1008. https://doi.org/10.1007/s10072-014-1628-5 CrossRef

176.

Bachewal P, Gundu C, Yerra VG, Kalvala AK, Areti A, Kumar A (2018) Morin exerts neuroprotection via attenuation of ROS induced oxidative damage and neuroinflammation in experimental diabetic neuropathy. BioFactors 44(2):109–122. https://doi.org/10.1002/biof.1397 CrossRefPubMed

177.

Mirshekar M, Roghani M, Khalili M, Baluchnejadmojarad T (2011) Chronic oral pelargonidin alleviates learning and memory disturbances in streptozotocin diabetic rats. Iran J Pharm Res IJPR 10(3):569–575PubMed

178.

Mirshekar M, Roghani M, Khalili M, Baluchnejadmojarad T, Arab Moazzen S (2010) Chronic oral pelargonidin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: involvement of oxidative stress. Iran Biomed J 14(1–2):33–39PubMedPubMedCentral

179.

Liu X, Mo Y, Gong J, Li Z, Peng H, Chen J, Wang Q, Ke Z, Xie J (2016) Puerarin ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Metab Brain Dis 31(2):417–423. https://doi.org/10.1007/s11011-015-9779-5 CrossRefPubMed

180.

Ola MS, Ahmed MM, Ahmad R, Abuohashish HM, Al-Rejaie SS, Alhomida AS (2015) Neuroprotective effects of rutin in streptozotocin-induced diabetic rat retina. J Mol Neurosci MN 56(2):440–448. https://doi.org/10.1007/s12031-015-0561-2 CrossRefPubMed

181.

Zhang S, Li H, Zhang L, Li J, Wang R, Wang M (2017) Effects of troxerutin on cognitive deficits and glutamate cysteine ligase subunits in the hippocampus of streptozotocin-induced type 1 diabetes mellitus rats. Brain Res 1657:355–360. https://doi.org/10.1016/j.brainres.2016.12.009 CrossRefPubMed

182.

Wang J, Wang L, Zhou J, Qin A, Chen Z (2018) The protective effect of formononetin on cognitive impairment in streptozotocin (STZ)-induced diabetic mice. Biomed Pharmacother Biomedecine pharmacotherapie 106:1250–1257. https://doi.org/10.1016/j.biopha.2018.07.063 CrossRefPubMed

183.

Cho SJ, Kang KA, Piao MJ, Ryu YS, Fernando P, Zhen AX, Hyun YJ, Ahn MJ, Kang HK, Hyun JW (2019) 7,8-Dihydroxyflavone protects high glucose-damaged neuronal cells against oxidative stress. Biomol Ther 27(1):85–91. https://doi.org/10.4062/biomolther.2018.202 CrossRef

184.

Wang H, Sun X, Zhang N, Ji Z, Ma Z, Fu Q, Qu R, Ma S (2017) Ferulic acid attenuates diabetes-induced cognitive impairment in rats via regulation of PTP1B and insulin signaling pathway. Physiol Behav 182:93–100. https://doi.org/10.1016/j.physbeh.2017.10.001 CrossRefPubMed

185.

Semaming Y, Sripetchwandee J, Sa-Nguanmoo P, Pintana H, Pannangpetch P, Chattipakorn N, Chattipakorn SC (2015) Protocatechuic acid protects brain mitochondrial function in streptozotocin-induced diabetic rats. Appl Physiol Nutr Metab Physiologie appliquee, nutrition et metabolisme 40(10):1078–1081. https://doi.org/10.1139/apnm-2015-0158 CrossRefPubMed

186.

Adedara IA, Fasina OB, Ayeni MF, Ajayi OM, Farombi EO (2019) Protocatechuic acid ameliorates neurobehavioral deficits via suppression of oxidative damage, inflammation, caspase-3 and acetylcholinesterase activities in diabetic rats. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 125:170–181. https://doi.org/10.1016/j.fct.2018.12.040 CrossRef

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction

Abstract

Background

Purpose

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Purpose

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

The combination of wheat peptides and fucoidan protects against chronic superficial gastritis and alters gut microbiota: a double-blinded, placebo-controlled study

Fluid and total water intake in a senior mediterranean population at high cardiovascular risk: demographic and lifestyle determinants in the PREDIMED-Plus study

Combined effect of interventions with pure or enriched mixtures of (poly)phenols and anti-diabetic medication in type 2 diabetes management: a meta-analysis of randomized controlled human trials

Dietary patterns associated with inflammatory biomarkers in a Northern German population

Effects of a formula with a probiotic Bifidobacterium lactis Supplement on the gut microbiota of low birth weight infants